At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 83 enrolled
Drug / intervention
IFN-alpha2adrug
Likely dose
IFN-alpha2a 90 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia)
In Brief
A Phase 2 clinical trial evaluating IFN-alpha2a for Myeloproliferative Disorders. Completed, enrolled 83 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to see if Pegasys (IFN-alpha2a) can help to control the disease in patients with ET, PV, AMM/MF, and Ph-negative CML. The safety of this treatment will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyeloproliferative Disorders
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2005
First PostedMar 2007
Primary CompletionMay 2023
TodayJul 2026
First PostedMar 26, 2007
Enrollment StartApr 7, 2005
Primary CompletionMay 26, 2023
TodayJul 2, 2026
Enrollment to primary: 18.1 yearsPosted 19.3 years ago
Interventions
IFN-alpha2adrug
Starting dose 90 microgram (mcg) injection under the skin once a week